Pharma News

Elimusertib by Bayer for Gastric Cancer: Likelihood of Approval

Elimusertib is under clinical development by Bayer and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Elimusertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Elimusertib overview

Elimusertib (BAY-1895344) is under development for the treatment of solid tumors such as ovarian cancer, colorectal cancer, hormone refractory castration resistant, androgen-independent prostate cancer, endometrial cancer, cervical cancer, fallopian tube cancer, peritoneal cancer, HER-2 negative breast cancer, triple-negative breast cancer, non-hodgkin lymphoma, mantle cell lymphoma, gastric cancer, non-small cell lung cancer, urothelial cancer, renal cancer, hepatocellular cancer, head and neck cancer, penile cancer, malignant pleural mesothelioma, small-cell lung cancer, biliary tract cancer, poorly differentiated neuroendocrine carcinoma (PD-NEC), pancreatic adenocarcinoma (PDA), rhabdomyosarcoma, Ewing sarcoma and lymphoma. It is administered orally. The drug candidate acts by targeting ataxia telangiectasia rad3-related protein (ATR).

Bayer overview

Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

For a complete picture of Elimusertib’s drug-specific PTSR and LoA scores, buy the report here.

Source link
#Elimusertib #Bayer #Gastric #Cancer #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *